02/02/23 8:02 AMNasdaq : PLRX Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid TumorsPliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment ofRHEA-AIneutral
01/27/23 4:03 PMNasdaq : PLRX offeringPliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesPliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the closing of its previously announced upsizedRHEA-AIneutral
01/25/23 8:01 AMNasdaq : PLRX managementPliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources OfficerPliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced Ms. Lily Cheung as its Chief Human ResourcesRHEA-AIneutral
01/24/23 9:19 PMNasdaq : PLRX offeringPliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underwritten publicRHEA-AIneutral
01/23/23 4:01 PMNasdaq : PLRX offeringPliant Therapeutics Announces Proposed Public Offering of Common StockPliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that it has commenced an underwritten publicRHEA-AIneutral
01/22/23 2:00 PMNasdaq : PLRX clinical trialPliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary FibrosisBexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No bexotegrast-treated patients experienced disease progression as defined by FVCpp decline of greater than or equal to 10% Bexotegrast was well tolerated over 12RHEA-AIneutral
01/03/23 8:00 AMNasdaq : PLRX conferencesPliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare ConferencePliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President andRHEA-AIneutral
12/15/22 8:00 AMNasdaq : PLRX Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary FibrosisPliant Therapeutics (NASDAQ: PLRX) announced today that its lead drug candidate, bexotegrast (PLN-74809), an oral, once daily, dual-selective αvß6/αvß1 integrin inhibitor, has received Orphan Drug Designation from the EuropeanRHEA-AIvery positive
11/15/22 8:00 AMNasdaq : PLRX conferencesPliant Therapeutics to Participate in Upcoming Investor ConferencesPliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following November investorRHEA-AIneutral
11/08/22 4:02 PMNasdaq : PLRX earningsPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsPliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2022RHEA-AIneutral